flu vaccine
03.09.2010
Drugmaker Abbott Laboratories has decided against the sale of its European flu-vaccine business after initial bids came in below its expectations, a company spokeswoman confirmed.
The auction had drawn interest from four or five bidders, but the offers came in at less than €500 million euros ($640 million) and proved too low for the company's liking, a person familiar with the matter told the newspaper.
more30.06.2010
Abbott Laboratories is exploring the sale of its flu vaccine unit acquired as part of its purchase of Solvay's drugs unit.
"Abbott is exploring the option to potentially sell the Solvay vaccines business," Abbott spokesman Scott Stoffel said.
The deal could fetch €500 million, the Wall Street Journal said, citing people familiar with the matter.
more